ABVC BioPharma Files 8-K: Material Agreement & Equity Sales

TL;DR

ABVC BioPharma signed a big deal and sold stock, filing an 8-K on 5/23/24.

AI Summary

On May 23, 2024, ABVC BioPharma, Inc. announced the entry into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and the equity sales were not provided in this initial filing.

Why It Matters

This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing indicates material agreements and equity sales, which can introduce financial and operational risks if not managed effectively.

Key Players & Entities

• ABVC BioPharma, Inc. (company) — Registrant
• May 23, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
• $0.75 — on Stock at a reduced exercise price of $0.75 per share. Lind will also receive a new
• $1.00 — the five-year anniversary thereof, for $1.00 per share (the " New Warrant "). The C
• $15,000 — set forth above, the Company shall pay $15,000 per week to Lind until the date the reg

Filing Documents

• ea0206715-8k_abvcbio.htm (8-K) — 32KB
• ea020671501ex10-1_abvcbio.htm (EX-10.1) — 52KB
• ea020671501ex10-2_abvcbio.htm (EX-10.2) — 89KB
• 0001213900-24-046313.txt ( ) — 382KB
• abvc-20240522.xsd (EX-101.SCH) — 3KB
• abvc-20240522_lab.xml (EX-101.LAB) — 33KB
• abvc-20240522_pre.xml (EX-101.PRE) — 22KB
• ea0206715-8k_abvcbio_htm.xml (XML) — 3KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, over the past year, ABVC BioPharma, Inc. (the " Company ") has entered into three securities purchase agreements with Lind Global Fund II, LP (" Lind "), pursuant to which the Company has issued to Lind: (i) 3,527,778 shares of the Company's common stock, par value $0.001 per share (the " Common Stock ") underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of February 23, 2023 between the Company and Lind (the "Lind Transaction"); (ii) 5,291,667 shares of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 342,857 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of November 17, 2023 between the Company and Lind (the "2 nd Lind Transaction"); (iv) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 2 nd Lind Transaction; (v) 285,714 shares of Common Stock of the Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and Lind (the "3 rd Lind Transaction," together with the Lind Transaction and 2 nd Lind Transaction, the "Initial Lind Transactions") and (vi) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant to the 3 rd Lind Transaction (all of the warrants issued to Lind are hereinafter referred to as the "Existing Warrants" and the shares of Common Stock issuable thereunder, are hereinafter referred to as the "Existing Shares"). On May 22, 2024, the Company and Lind entered into a letter agreement (the " Agreement "), pursuant to which Lind will exercise, for cash, 1,000,000 of the Existing Warrants (the number of warrants so exercised is herein referred to as the " Outstanding Exercised Warrants ") to purchase shares of Common Stock at a

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 10.1 Letter Agreement 10.2 Form of Warrant 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. May 23, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR